GHK-Cu peptide claims on TikTok: what the science actually says

What did @pepperjourneymalaysia actually say?

The creator, who identifies as a "GPP1 engineer," argues that hitting muscle during subcutaneous GLP-1 injections is "almost going to be impossible" even with the longest 12mm needle. They cite a real ultrasound study by Gibney et al. (2010) to show that skin and subcutaneous tissue depth far exceeds typical needle lengths across the abdomen, arms, and thighs. Their bottom line: "any needle size from 4 to 12 seems to be safe for subcutaneous use."

This is a reasonable practical question. People using GLP-1 receptor agonists like semaglutide worry about intramuscular injection because it can affect absorption rates, cause more pain, and may alter the pharmacokinetic profile of the drug. The creator is trying to reassure viewers who received conflicting advice in their comments. That's a legitimate goal, and they at least anchor it in a published study rather than just vibes.

Does the science back this up?

Mostly, yes, but with real caveats the creator glosses over. The Gibney et al. (2010) study in Diabetes Technology and Therapeutics did use ultrasound to map skin and subcutaneous tissue thickness across multiple body sites, and the general numbers the creator quotes are in the right ballpark. Subcutaneous fat depth in the abdomen averages well above 10mm in most adults, making intramuscular injection with a 4-8mm needle genuinely unlikely.

However, the critical variable is body composition. A 2014 study by Hirsch et al. in Diabetes Care found that lean individuals, particularly in the arm and thigh, can have subcutaneous fat layers thin enough that even an 8mm needle risks intramuscular delivery if inserted at 90 degrees without a skin fold. The Gibney data shows averages, not minimums. For a thin adult injecting into the deltoid area with a 12mm needle at 90 degrees, intramuscular injection is not "almost impossible." It is a real possibility. The creator's flat reassurance that 4-12mm is universally safe oversimplifies this.

What did they get wrong (or right)?

They got the core anatomy right. Skin dermis and epidermis averaging 2-2.2mm, with subcutaneous layers ranging from roughly 10mm in the arm and thigh to 40mm in the abdomen, matches the Gibney et al. findings. Credit where it's due: citing an actual peer-reviewed ultrasound study beats the usual anecdote-based injection advice that circulates on social media.

Where they went wrong is the universalizing language. Saying "it is almost going to be impossible" to hit muscle with a 12mm needle ignores lean body types entirely. The Gibney study itself noted substantial inter-individual variation. A 12mm needle inserted perpendicular to the skin in a lean arm absolutely can reach muscle. Injection angle matters too. The Forum for Injection Technique (FIT) recommends a 45-degree angle or pinched skin fold for 8mm and longer needles specifically to reduce intramuscular risk in leaner patients. The creator does not mention either technique.

The title framing, "biggest sized needles," is also vague. Insulin needle lengths go up to 12mm in common use, but technique and patient body composition are the bigger determinants of injection depth than needle length alone.

What should you actually know?

If you are self-injecting a subcutaneous peptide or GLP-1 medication, needle length is only one part of the equation. Body fat distribution, injection site, needle angle, and whether you lift a skin fold all affect whether the drug lands in subcutaneous tissue or muscle. For most adults injecting into the abdomen with a 4-8mm needle, intramuscular injection is unlikely. For leaner individuals using longer needles in the arm or thigh, the risk is real and not negligible.

Current injection technique guidelines from organizations like the FIT Recommendations (Frid et al., 2016, Diabetes Metabolism) suggest that 4mm and 5mm pen needles are appropriate for most adults without a skin fold lift, while needles 8mm or longer should use a 45-degree angle or pinched fold to reduce intramuscular risk. These are the practical numbers the creator should have mentioned.

• Use the shortest needle that works for your body type and site.
• If you are lean, consider a 45-degree angle or skin fold lift for any needle 8mm or longer.
• The abdomen is generally the safest site for subcutaneous injection across body types.
• Accidental intramuscular injection of subcutaneous medications is not always harmful, but it can alter absorption and cause more localized discomfort.